Milestone Pharmaceuticals (MIST) Projected to Post Quarterly Earnings on Tuesday

Milestone Pharmaceuticals (NASDAQ:MIST) is anticipated to release its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect Milestone Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:00 AM ET.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts expect Milestone Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Milestone Pharmaceuticals Stock Up 0.3%

NASDAQ:MIST traded up $0.01 during midday trading on Tuesday, hitting $1.86. The stock had a trading volume of 252,162 shares, compared to its average volume of 1,609,029. The stock has a 50-day moving average of $1.93 and a 200 day moving average of $1.70. The company has a market capitalization of $157.66 million, a price-to-earnings ratio of -2.21 and a beta of 0.54. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $2.75.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MIST. Wells Fargo & Company started coverage on Milestone Pharmaceuticals in a report on Thursday, September 11th. They issued an “overweight” rating and a $4.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Milestone Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $4.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. Raymond James Financial Inc. raised its position in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 30.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 43,235 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Raymond James Financial Inc. owned approximately 0.08% of Milestone Pharmaceuticals worth $84,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.